A July 9 attorney-advertising press release says Monteverde & Associates is probing proposed deals involving Theravance Biopharma, Iridium Communications, LCI Industries and Patrick Industries, and outlines the stated shareholder consideration.
Monteverde & Associates PC said it is investigating four proposed transactions involving Theravance Biopharma, Iridium Communications, LCI Industries and Patrick Industries. Under the terms described in the July 9, 2026 press release, Theravance Biopharma shareholders are expected to receive $176.00 per share in cash and one contingent value right in the company’s sale to Zymeworks, while Iridium Communications shareholders are expected to receive $27.00 in cash plus Rocket Lab common stock determined by an exchange ratio. LCI Industries shareholders are expected to receive 1.2440 shares of Patrick common stock for each LCI share, and Patrick Industries shareholders are expected to own about 52% of the combined company after the merger closes. The firm said the inquiries are being handled by Juan Monteverde of Monteverde & Associates PC, which the release described as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.